samedan logo

home > news > detailed info

Altasciences Chosen by Respira Technologies, Inc. as Drug Product Manufacturing Partner for the World’s First Inhaled Nicotine Replacement Therapy (NRT)


Laval, Quebec, December 14, 2021
– Altasciences’ pharmaceutical contract manufacturing site in Philadelphia, PA, has been chosen by Respira Technologies, Inc. to manufacture proprietary drug products for the world’s first inhaled smoking cessation therapy. This treatment uses RespiRx™, a vibrating mesh nebulizer (VMN) with a maintenance-free disposable cartridge that reduces and potentially eliminates the risk of patient misuse and non-compliance.

Following a successful Pre-Investigational New Drug (IND) meeting with the Food and Drug Administration (FDA) on November 18, Respira is intending to submit their IND application in 2022 under the 505(b)(2) regulatory pathway.

Respira also plans to create a larger platform approach for active pharmaceutical ingredient (API) delivery, taking advantage of the multi-drug capabilities of their proprietary platform drug delivery system. To date, 91 potential APIs have been identified.

“Our team chooses best-in-class partners, and working with Altasciences has been a great experience overall. Altasciences is playing a big role in advancing Respira’s ambition to secure the FDA’s authorization on a potential breakthrough drug product, and through this collaborative environment, we can change the world of drug development. Altasciences is agile, flexible, and quick, while providing the proven expertise and capability required for cGMP pharma drug product manufacturing. We are thankful for their fast response rate, creativity, and ability to take on the needs of nimble start-ups like Respira,” said Mario Danek, Founder and CEO at Respira Technologies, Inc.

Altasciences leverages deep expertise in formulation, development, and manufacturing, as well as flexible processes and significant investments in state-of-the-art technologies, to support clients in their research and commercial manufacturing requirements.

“We are delighted to be partnering with Respira Technologies, Inc. on this new and exciting technology. Our team has truly enjoyed having the opportunity to work with a world-class organization that quickly makes key decisions to ensure we meet accelerated timelines,” stated Ben Reed, Executive Vice President of Operations at Altasciences.

More information on Respira Technologies, Inc.’s program can be found here.
phone 450 973-6077
email 575 Armand-Frappier Blvd. Laval, QC H7V 4B3 Canada
Print this page
Send to a friend
News and Press Releases

Biognosys Partners With Kymera Therapeutics in Precision Proteomics Biomarkers

March 15, 2022 – ZURICH – Business Wire. Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, and Kymera Therapeutics, a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD), announced today that they are broadly collaborating across preclinical studies and clinical trials.
More info >>

White Papers

Assessing the Integrity of Pharmaceutical Packaging Using the Sepha Blisterscan and Conventional Blue Dye Leak Testing Methods

Sepha Limited

A new whitepaper by a leading packaging expert from the University of Ulster, Dr Dorian Dixon, into the integrity of pharmaceutical packaging has established that existing methods for testing the seal integrity of blister packs are not as accurate as newer, technology based test equipment.
More info >>

Industry Events

Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022)

20-21 June 2022, Berlin, Germany

Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022) is held on June, 20-21, 2022 in Berlin, Germany. The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies to discuss the manufacturing and packaging processes of the pharmaceutical industry. Among the participating companies are Bayer, Sandoz, Merck, Novartis, Roche, Genveon, Samsung Biologics, Pfizer.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement